Peptide vaccines for leishmaniasis.

Detalhes bibliográficos
Autor(a) principal: Brito, Rory Cristiane Fortes de
Data de Publicação: 2018
Outros Autores: Cardoso, Jamille Mirelle de Oliveira, Reis, Levi Eduardo Soares, Vieira, João Filipe Pereira, Mathias, Fernando Augusto Siqueira, Roatt, Bruno Mendes, Soares, Rodrigo Dian de Oliveira Aguiar, Ruiz, Jeronimo Conceição, Resende, Daniela de Melo, Reis, Alexandre Barbosa
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFOP
Texto Completo: http://www.repositorio.ufop.br/handle/123456789/10828
Resumo: Due to an increase in the incidence of leishmaniases worldwide, the development of new strategies such as prophylactic vaccines to prevent infection and decrease the disease have become a high priority. Classic vaccines against leishmaniases were based on live or attenuated parasites or their subunits. Nevertheless, the use of whole parasite or their subunits for vaccine production has numerous disadvantages. Therefore, the use of Leishmania peptides to design more specific vaccines against leishmaniases seems promising. Moreover, peptides have several benefits in comparison with other kinds of antigens, for instance, good stability, absence of potentially damaging materials, antigen low complexity, and low-cost to scale up. By contrast, peptides are poor immunogenic alone, and they need to be delivered correctly. In this context, several approaches described in this review are useful to solve these drawbacks. Approaches, such as, peptides in combination with potent adjuvants, cellular vaccinations, adenovirus, polyepitopes, or DNA vaccines have been used to develop peptide-based vaccines. Recent advancements in peptide vaccine design, chimeric, or polypeptide vaccines and nanovaccines based on particles attached or formulated with antigenic components or peptides have been increasingly employed to drive a specific immune response. In this review, we briefly summarize the old, current, and future stands on peptide-based vaccines, describing the disadvantages and benefits associated with them. We also propose possible approaches to overcome the related weaknesses of synthetic vaccines and suggest future guidelines for their development.
id UFOP_c8cfc80feb5287d90f3c44e79866ba29
oai_identifier_str oai:localhost:123456789/10828
network_acronym_str UFOP
network_name_str Repositório Institucional da UFOP
repository_id_str 3233
spelling Brito, Rory Cristiane Fortes deCardoso, Jamille Mirelle de OliveiraReis, Levi Eduardo SoaresVieira, João Filipe PereiraMathias, Fernando Augusto SiqueiraRoatt, Bruno MendesSoares, Rodrigo Dian de Oliveira AguiarRuiz, Jeronimo ConceiçãoResende, Daniela de MeloReis, Alexandre Barbosa2019-03-26T16:58:25Z2019-03-26T16:58:25Z2018BRITO, R. C. F. de et al. Peptide vaccines for leishmaniasis. Frontiers in Immunology, v. 9, p. 1043, maio 2018. Disponível em: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958606/pdf/fimmu-09-01043.pdf>. Acesso em: 20 fev. 2019.16634365http://www.repositorio.ufop.br/handle/123456789/10828Due to an increase in the incidence of leishmaniases worldwide, the development of new strategies such as prophylactic vaccines to prevent infection and decrease the disease have become a high priority. Classic vaccines against leishmaniases were based on live or attenuated parasites or their subunits. Nevertheless, the use of whole parasite or their subunits for vaccine production has numerous disadvantages. Therefore, the use of Leishmania peptides to design more specific vaccines against leishmaniases seems promising. Moreover, peptides have several benefits in comparison with other kinds of antigens, for instance, good stability, absence of potentially damaging materials, antigen low complexity, and low-cost to scale up. By contrast, peptides are poor immunogenic alone, and they need to be delivered correctly. In this context, several approaches described in this review are useful to solve these drawbacks. Approaches, such as, peptides in combination with potent adjuvants, cellular vaccinations, adenovirus, polyepitopes, or DNA vaccines have been used to develop peptide-based vaccines. Recent advancements in peptide vaccine design, chimeric, or polypeptide vaccines and nanovaccines based on particles attached or formulated with antigenic components or peptides have been increasingly employed to drive a specific immune response. In this review, we briefly summarize the old, current, and future stands on peptide-based vaccines, describing the disadvantages and benefits associated with them. We also propose possible approaches to overcome the related weaknesses of synthetic vaccines and suggest future guidelines for their development.This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Fonte: o próprio artigoinfo:eu-repo/semantics/openAccessTegumentary leishmaniasesPeptide-based vaccinesChimeric vaccineVisceral leishmaniasisPolypeptide vaccinesPeptide vaccines for leishmaniasis.info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleengreponame:Repositório Institucional da UFOPinstname:Universidade Federal de Ouro Preto (UFOP)instacron:UFOPLICENSElicense.txtlicense.txttext/plain; charset=utf-8924http://www.repositorio.ufop.br/bitstream/123456789/10828/2/license.txt62604f8d955274beb56c80ce1ee5dcaeMD52ORIGINALARTIGO_PeptideVaccinesLeishmaniasis.pdfARTIGO_PeptideVaccinesLeishmaniasis.pdfapplication/pdf786046http://www.repositorio.ufop.br/bitstream/123456789/10828/1/ARTIGO_PeptideVaccinesLeishmaniasis.pdfe783b9612eda484a7a72922d591d6db6MD51123456789/108282019-03-26 12:58:25.957oai:localhost: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ório InstitucionalPUBhttp://www.repositorio.ufop.br/oai/requestrepositorio@ufop.edu.bropendoar:32332019-03-26T16:58:25Repositório Institucional da UFOP - Universidade Federal de Ouro Preto (UFOP)false
dc.title.pt_BR.fl_str_mv Peptide vaccines for leishmaniasis.
title Peptide vaccines for leishmaniasis.
spellingShingle Peptide vaccines for leishmaniasis.
Brito, Rory Cristiane Fortes de
Tegumentary leishmaniases
Peptide-based vaccines
Chimeric vaccine
Visceral leishmaniasis
Polypeptide vaccines
title_short Peptide vaccines for leishmaniasis.
title_full Peptide vaccines for leishmaniasis.
title_fullStr Peptide vaccines for leishmaniasis.
title_full_unstemmed Peptide vaccines for leishmaniasis.
title_sort Peptide vaccines for leishmaniasis.
author Brito, Rory Cristiane Fortes de
author_facet Brito, Rory Cristiane Fortes de
Cardoso, Jamille Mirelle de Oliveira
Reis, Levi Eduardo Soares
Vieira, João Filipe Pereira
Mathias, Fernando Augusto Siqueira
Roatt, Bruno Mendes
Soares, Rodrigo Dian de Oliveira Aguiar
Ruiz, Jeronimo Conceição
Resende, Daniela de Melo
Reis, Alexandre Barbosa
author_role author
author2 Cardoso, Jamille Mirelle de Oliveira
Reis, Levi Eduardo Soares
Vieira, João Filipe Pereira
Mathias, Fernando Augusto Siqueira
Roatt, Bruno Mendes
Soares, Rodrigo Dian de Oliveira Aguiar
Ruiz, Jeronimo Conceição
Resende, Daniela de Melo
Reis, Alexandre Barbosa
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Brito, Rory Cristiane Fortes de
Cardoso, Jamille Mirelle de Oliveira
Reis, Levi Eduardo Soares
Vieira, João Filipe Pereira
Mathias, Fernando Augusto Siqueira
Roatt, Bruno Mendes
Soares, Rodrigo Dian de Oliveira Aguiar
Ruiz, Jeronimo Conceição
Resende, Daniela de Melo
Reis, Alexandre Barbosa
dc.subject.por.fl_str_mv Tegumentary leishmaniases
Peptide-based vaccines
Chimeric vaccine
Visceral leishmaniasis
Polypeptide vaccines
topic Tegumentary leishmaniases
Peptide-based vaccines
Chimeric vaccine
Visceral leishmaniasis
Polypeptide vaccines
description Due to an increase in the incidence of leishmaniases worldwide, the development of new strategies such as prophylactic vaccines to prevent infection and decrease the disease have become a high priority. Classic vaccines against leishmaniases were based on live or attenuated parasites or their subunits. Nevertheless, the use of whole parasite or their subunits for vaccine production has numerous disadvantages. Therefore, the use of Leishmania peptides to design more specific vaccines against leishmaniases seems promising. Moreover, peptides have several benefits in comparison with other kinds of antigens, for instance, good stability, absence of potentially damaging materials, antigen low complexity, and low-cost to scale up. By contrast, peptides are poor immunogenic alone, and they need to be delivered correctly. In this context, several approaches described in this review are useful to solve these drawbacks. Approaches, such as, peptides in combination with potent adjuvants, cellular vaccinations, adenovirus, polyepitopes, or DNA vaccines have been used to develop peptide-based vaccines. Recent advancements in peptide vaccine design, chimeric, or polypeptide vaccines and nanovaccines based on particles attached or formulated with antigenic components or peptides have been increasingly employed to drive a specific immune response. In this review, we briefly summarize the old, current, and future stands on peptide-based vaccines, describing the disadvantages and benefits associated with them. We also propose possible approaches to overcome the related weaknesses of synthetic vaccines and suggest future guidelines for their development.
publishDate 2018
dc.date.issued.fl_str_mv 2018
dc.date.accessioned.fl_str_mv 2019-03-26T16:58:25Z
dc.date.available.fl_str_mv 2019-03-26T16:58:25Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv BRITO, R. C. F. de et al. Peptide vaccines for leishmaniasis. Frontiers in Immunology, v. 9, p. 1043, maio 2018. Disponível em: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958606/pdf/fimmu-09-01043.pdf>. Acesso em: 20 fev. 2019.
dc.identifier.uri.fl_str_mv http://www.repositorio.ufop.br/handle/123456789/10828
dc.identifier.issn.none.fl_str_mv 16634365
identifier_str_mv BRITO, R. C. F. de et al. Peptide vaccines for leishmaniasis. Frontiers in Immunology, v. 9, p. 1043, maio 2018. Disponível em: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958606/pdf/fimmu-09-01043.pdf>. Acesso em: 20 fev. 2019.
16634365
url http://www.repositorio.ufop.br/handle/123456789/10828
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFOP
instname:Universidade Federal de Ouro Preto (UFOP)
instacron:UFOP
instname_str Universidade Federal de Ouro Preto (UFOP)
instacron_str UFOP
institution UFOP
reponame_str Repositório Institucional da UFOP
collection Repositório Institucional da UFOP
bitstream.url.fl_str_mv http://www.repositorio.ufop.br/bitstream/123456789/10828/2/license.txt
http://www.repositorio.ufop.br/bitstream/123456789/10828/1/ARTIGO_PeptideVaccinesLeishmaniasis.pdf
bitstream.checksum.fl_str_mv 62604f8d955274beb56c80ce1ee5dcae
e783b9612eda484a7a72922d591d6db6
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFOP - Universidade Federal de Ouro Preto (UFOP)
repository.mail.fl_str_mv repositorio@ufop.edu.br
_version_ 1801685718766977024